January 15, 2021

Offering delicious products
for the sound mind and body

Company:
Representative:
Inquiries:

DyDo Group Holdings, Inc.
Tomiya Takamatsu, President(Code 2590 on the First Section of the Tokyo Stock Exchange)
Naokazu Hasegawa, Corporate Officerand General Manager of Corporate Communication Department

Notice of a Consolidated Subsidiary’s Entry into a Licensing Agreement
DyDo Pharma, Inc., a consolidated subsidiary of DyDo Group Holdings, has entered, effective today,
into a licensing agreement with CellGenTech, Inc., for commercialization of LCAT-GMAC (geneticallymodified human adipocyte of LCAT), a promising novel treatment for familial LCAT deficiency.
Having identified the healthcare market, including the rapidly-growing life science field, as its next
growth domain, the DyDo Group established DyDo Pharma in January 2019 in an effort to focus onpharmaceuticals for treating rare diseases (diseases which affect 50,000 or fewer patients in Japan). Suchdiseases, for which there are as yet no effective treatment options, have become a social issue. The
licensing agreement is the first for DyDo Pharma, which has been working to secure a promising productpipeline in an effort to develop pharmaceutical drugs for rare congenital diseases and ultra-rare diseases,
which have even fewer patients, in order to address this issue.
Please see the separate press release for more information about the agreement.
As the effect of this licensing agreement on consolidated performance during the fiscal year ending
January 2021 has already been incorporated into the full-year performance outlook that was announced on
November 26, 2020, that outlook remains unchanged.

January 15, 2021
For immediate release
CellGenTech, Inc.
DyDo Pharma, Inc.

Notice of Licensing Agreement for LCAT-GMAC (genetically modified human adipocyteof LCAT)
CellGenTech, Inc., (head office: Chuo-ku, Chiba; president & CEO: Masayuki Aso) and DyDo Pharma,Inc., (head office: Kita-ku, Osaka; president and representative director: Yasunori Inaoka) are pleased toannounce that they have entered, effective today, into a licensing agreement under which they will jointly
and exclusively pursue the development and sale in Japan of LCAT-GMAC (genetically modified
human adipocyte of LCAT), a promising treatment for familial LCAT deficiency that is being developedby CellGenTech.
LCAT-GMAC is being developed by CellGenTech with research support from “Medical Research andDevelopment Programs Focused on Technology Transfer Adaptable and Seamless Technology
Transfer Program through Target-Driven Research and Development,” a program of the Japan
Agency for Medical Research and Development (AMED). By entering into this agreement with AMED andother entities, CellGenTech and DyDo Pharma entered have acquired a license to commercialize the resultsof that R&D effort.
Founded in 2003, CellGenTech, a biotech venture with an origin in Chiba University, has pioneered
development of pharmaceuticals using human adipocytes. The company, which is dedicated to helping
improve quality of life for patients suffering from difficult-to-treat diseases and their family members,offers treatment using genetically modified human adipocytes (“GMACs”), which are created bytransfection of genes that supply proteins used to treat disease to human adipocytes, in order to treat
disorders caused by genetic or acquired deficiency or reduced functionality of proteins with physiologicalfunctions.
CellGenTech president and CEO Masayuki Aso described the licensing agreement as follows:“LCAT deficiency is a rare and difficult-to-treat disease. Currently, Chiba University is conducting theclinical trials for LCAT-GMAC in cooperation with us in order to develop a gene therapy and regenerative
medicine as the world's first treatment for LCAT deficiency. By taking advantage of the life span of humanadipocytes, LCAT-GMAC will be expected that it secrets normal LCAT in the body for several years andimproves or halts the progression of various symptoms caused by LCAT deficiency and reduced function
by its once implantation/administration. LCAT-GMAC will be a medicine that realizes true regenerative
medicine. By entering into a license agreement that covers joint development and sales with DyDo Pharma,
which is dedicated to contributing to the treatment of rare diseases, we will add momentum to thedevelopment of the product, allowing us to offer it to healthcare providers sooner so that we can make acontribution to patients and their families. We at CellGenTech look forward to contributing to healthcare byapplying the basic technology underlying GMAC to the development of treatments for other rare anddifficult-to-treat diseases.”DyDo Pharma president and representative director Yasunori Inaoka amplified President Aso'scomments:“We expect that partnering with CellGenTech in the joint development and sale of LCAT-GMAC will
help us offer a new treatment option to patients suffering from familial LCAT deficiency for which there isno cure yet, and their families. Going forward, we’ll be pursuing joint development with CellGenTech toobtain marketing authorization approval so that we can supply this cell and gene therapy to patients as soon
as possible.”(Reference information)
Familial LCAT deficiency
Familial LCAT (Lecithin Cholesterol Acyltransferase) deficiency is a disease in which the LCAT
enzyme, which plays a role in the process by which cholesterol that is not needed in the body is captured
by HDL cholesterol and sent to the liver for processing, fails to function sufficiently due to a genetic
deficiency or mutation. As a result, unnecessary cholesterol that remains unprocessed has an adverse
effect on bodily tissues, causing symptoms such as corneal opacity, hemolytic anemia, and renaldysfunction. In particular, the condition brings increased risk of serious conditions such as visual field
constriction due to corneal opacity and renal failure due to renal dysfunction. The disease, which is
caused by an abnormality of the LCAT gene on the chromosomes, affects about one in a million people.
Currently, there are no effective treatments for familial LCAT deficiency, leaving only dietary therapy,
which seeks to delay progression of the disease through a low-fat diet.

Media inquiries
Business Development, CellGenTech Tokyo
CellGenTech, Inc.
5th floor, Suidobashi South Building
2-7-9 Nishikanda, Chiyoda-ku, Tokyo 101-0065
Phone: +81-3-5212-8885
Fax: +81-3-5212-8877
Corporate Communications Department
DyDo Group Holdings, Inc.
18th floor, Nakanoshima Central Tower
2-2-7 Nakanoshima, Kita-ku, Osaka 530-0005
Phone: +81-6-7166-0077
Fax: +81-6-6222-2623